A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease activity and lowered steroid use in people with systemic lupus erythematosus (SLE), the most common form of lupus. The results were also presented today at the 15th European Lupus Society meeting, SLEuro 2026.
More than 75% of people treated with Gazyva plus standard therapy achieved at least a four-point improvement in the SLE Responder Index (SRI-4) — a measurement tool that evaluates disease severity and symptoms — compared with 53.5% with placebo plus standard therapy. Currently, Gazyva is approved in the U.S. and European Union for the treatment of adults with active lupus nephritis.
Tags: obinutuzumab, New England Journal of Medicine, NEJM, Gzyva, SLEuro 2026, Genentech